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The Role of miRNA in Diagnostics 




Whilst the promise of RNA interference (RNAi) continues to expand in the therapeutic 
environment, the utility of the endogenous RNAi mechanism, microRNAs (miRNA), in 
diagnostics has been proven with the successful commercialisation of a biopsy assay for the 
identification of cancer of unknown primary origin (CUP). The implications and 
consequences in personalised medicine arising from this highly sensitive and specific 
approach are substantial, however the true potential is only beginning to be understood, as 
reports of disease-specific miRNA signatures in circulating lymphocytes, blood 
plasma/serum, lung sputum, saliva and urine have been described, even in diseases where no 
diagnostic tools exist. This review summarises the various approaches in miRNA biomarker 




MicroRNA’s (miRNA) are a novel class of endogenous RNA regulators of gene expression. 
The 721 miRNA so far described in man (miRBase v.14, http://www.mirbase.org/) are found 
in non-coding genes individually or in clusters, with some exceptions processed from protein-
coding transcripts. A transcript encoding a miRNA (primary miRNA) is processed in the 
nucleus into the miRNA precursor (pre-miR), a stem-loop hairpin RNA of ~70 nucleotides. 
The pre-miR is actively exported to and processed into the mature miRNA in the cytoplasm. 
This double stranded RNA (dsRNA) features i) a length usually between 21-25 bp, ii) at least 
one mismatch and iii) at least one 3’ end overhang. One strand is then loaded onto an 
Argonaute protein, forming the miRNA-induced silencing complex (mi-RISC) [1].  
In a mechanism almost identical to that of short interfering RNAs (siRNA), mi-RISC 
complexes ‘scan’ the 3’ un-translated regions (UTR) of mRNA’s for complementarity to the 
miRNA. Substantial complementarity identifies a miRNA recognition element (MRE) and 
miRISC sequesters the mRNA preventing translation, or mediating eventual degradation [2]. 
Bases 2-7 from the 5’ end of the miRNA, known as the ‘seed’ region, drive most MRE 
identifications [3], however this is not exclusive [4]. The seed region size suggests that 
hundreds of proteins might be regulated by each miRNA and algorithms are routinely used 
for bioinformatic target prediction [5]. However, additional mechanisms of miRNA-mediated 
gene expression regulation exist, including mRNA 5’-UTR interactions and chromatin 
modification [6].  
The plethora of miRNA targets suggests a tight network of molecular interactions 
orchestrating protein expression, with miRNAs constituting crucial nodes. This is manifest in 
the established roles of specific miRNAs in cellular and physiological processes in the central 
nervous system, immune system, heart and skeletal muscle, diabetes and metabolism, etc. [7].  
Additionally, at least 176 miRNAs are also found in human viruses (miRBase v. 14), which 
also encode protein suppressors of RNAi [8, 9]. Similar functions have also been described 
for intracellular bacterial pathogens, so far only in plants [10]. Importantly, both miRNA and 
their mRNA targets are highly conserved between species. Thus, miRNA signatures 
associated with a specific biological condition (e.g. inflammation) tend to be conserved 
across species of interest. Notwithstanding the therapeutic opportunities presented in 
restoring deregulated miRNA expression, there is the potential for miRNA signatures to be 
used not only as cross-species biomarkers of disease, for toxicology analysis and drug safety 
monitoring, but also as prognostic factors, to assist in the classification of disease and as 
markers of drug efficacy. 
 
Approaches and considerations in miRNA profiling 
Numerous specialist and commercially available methodologies for miRNA transcriptome 
(miRnome) profiling have been developed. These can be broadly grouped into three 
categories: quantitative polymerase chain reaction (qPCR), hybridization assays and 
sequencing (see table 1). The technological differences between each technique may result in 
profiling data that differ between platforms; e.g. an adenosine to inosine editing event [11] 
which could impact on a qPCR assay could go undetected through microarray profiling, as 
has been highlighted in mRNA profiling [12]. The most advanced and sensitive method 
currently available is next generation sequencing (NGS), a collection of platform 
technologies that perform up to 50 x 109 base reads per run [13], building a comprehensive, 
quantitative picture of microRNA and other small non-coding RNA profiles.  
 
Table 1: Comparative assessment of microRNA profiling technology platforms 
 
The nature of the sample can similarly impact on miRnome profiles. Thus, whereas in 
isolated lung epithelia nuclear factor kappa B (NF-κB) pathway-mediated inflammation 
results in induction of miR-146 [14], this is not detected at the whole lung level [15]. On the 
other hand miRNA levels have been shown to be diurnally expressed in the brain [16], the 
retina [17] and the liver [18], with changes detected either at the pre-miR or mature miRNA 
level [19]. In the context of disease, in transient focal cerebral ischemia, the observed 
miRnome changes were reversed within 48 hours [20]. MicroRNA response onset might also 
precede cellular responses in vivo [15], whereas in vitro rapid oscillations (T < 1 hr) have 
been reported [21]. Collectively, these studies indicate that miRNA profiling should be 
approached with the same considerations pertinent to classical gene expression profiling.  
 
miRNA profiling in disease; the cancer paradigm 
By the end of 2009 over 1600 peer-reviewed articles and 500 reviews had been published 
associating miRNA deregulation in cancer, with four cancer biomarker assays having become 
commercially available. These covered the identification of pancreatic cancer over 
pancreatitis [22], the differentiation of squamous vs. non-squamous lung cancer [23], 
malignant pleural mesothelioma from cancers of the lung and the pleura [24], and the 
identification of the tissue of origin for metastatic cancers of unknown primary origin (CUP) 
[25]. With assay sensitivity and specificity in excess of 90%, these assays addressed up to 
30% error rates in diagnosis, an important step forward towards personalised medicine. 
Crucially, several studies have now demonstrated associations of miRnome signatures with 
various aspects of cancer, including disease progression, survival prediction and treatment 
selection and efficacy (for an in depth review see [26]).  
 
Disease diagnosis and classification through biopsy miRNA profiling 
In a study examining the involvement of miRNA in primary biliary cirrhosis (PBC) a 
microarray platform was used to demonstrate the deregulation of 35 miRNA in six end-stage 
PBC patients vs. five healthy controls [27]. The findings for at least three downregulated 
(miR-122a, miR-26a and miR-99a) and three upregulated (miR-299-5p, miR-328 and miR-
371) miRNAs were then validated in an expanded sample population by qPCR. Whilst of the 
affected miRNAs, loss of miR-122 expression alone has been shown to be associated with 
liver disease (see table 2), the remaining PBC miRnome signature was not directly ascribed 
to the disease on account of the complex physiology of end-stage PBC.  
The extent to which a biopsy can always yield a diagnostic miRnome signature was put to the 
question in a study investigating miRNA signatures in mild asthma [28]. qPCR screening in 
bronchial biopsies failed to identify any significant changes either in disease, or following 
treatment. The absence of disease or pharmacodynamic signatures was ascribed to the 
heterogeneity in the cell population constituting the biopsy and the potential lack of treatment 
effect on mild asthma miRNA homeostasis. Thus, whilst homogeneous tissue biopsies such 
as from the liver might yield clear disease signatures, this study demonstrates the urgent need 
for methodologies that allow cell-type specific analysis of biomarker expression.  
Elsewhere, the expression of 365 miRNAs was evaluated by Taqman as a means of 
predicting renal allograft rejection and function [29]. Of the 17 miRNAs differentially 
expressed in a training sample set (4 normal, 3 acute rejection biopsies), 6 were validated 
using an independent set of 26 biopsies (9 acute rejection, 17 normal), identifying over-
expression of miR-155 and miR-142-5p as acute rejection status predictors at 100% 
sensitivity and 95% specificity. The inflammatory cell component in this disease was 
considered accountable for the observed upregulation of miR-155, miR-142-5p and miR-223, 
well-described components of the lymphocyte compartment miRnome [30]. Curiously, the 
authors observed these miRNAs as highly expressed also in peripheral blood mononuclear 
cells (PBMC) [29], suggesting biomarker identification might be possible to carry out 
peripherally. 
 miRNA biomarkers in circulating cells and biofluids  
To date there is no single laboratory-based assay for effective diagnosis of systemic lupus 
erythematosus (SLE). Moreover, discrimination of SLE from immune thrombocytopenic 
purpura (ITP) is complicated by common symptomatology and similar lack of diagnostic 
assays. Using microarrays, 16 miRNAs differentially regulated in SLE patient PBMCs was 
observed [31]. Moreover, the reduction of expression for 8 miRNA was found to correlate 
with increase in SLE severity. Similarly, 19 miRNA were found to be deregulated in ITP. 
Whilst a common signature was observed for 11 miRNA, downregulation of miR-184 and 
upregulation of miR-198 and miR-21 were specific to SLE, whereas downregulation of 6 
miRNAs was specific to ITP. Whilst a large training set was used, biomarker validation was 
not carried out. Moreover, comparison to the PBMC miRnome profiles of other autoimmune 
diseases is needed to substantiate the utility of these signatures in SLE and ITP diagnosis and 
discrimination. Encouragingly, deregulation in the expression of 66 miRNA in renal biopsies 
of Lupus nephritis patients, a common complication of SLE [32], has also been described, 
though the PBMC signature was not reflected in the kidney.  
 
Table 2: miRNA biomarker assays proposed for physiological condition and disease 
diagnosis. 
 
MicroRNA profiling studies have also been extensively carried out in rheumatoid arthritis 
(RA). Similar to acute allograft rejection, miR-155 and miR-146a was upregulated in RA 
synovial fibroblasts, synovial tissue and synovial macrophages when compared to 
osteoarthritis (OA) samples [33]. Elsewhere, miR-146a was also observed to be 
overexpressed in RA synovial tissue as compared to OA, primarily but not exclusively in the 
lymphocyte infiltrate [34]. In addition to miR-155 and miR-146a, increased miR-132 and 
miR-16 expression was also observed in a separate study in RA patient PBMC’s [35], 
whereas in peripheral CD4+ T lymphocytes miR-223 was the only deregulated miRNA [36]. 
miR-146a is emerging as a hallmark of severe inflammation [14] whose deregulation might 
underlie aspects of aberrant proinflammatory cytokine expression [35, 37]. However, it is 
worth noting that whilst the same cellular infiltrate might mediate similar tissue damage, the 
precise immunological milieu may differ sufficiently to warrant distinct miRnome profiles 
[38].  
An inflammatory and innate immune response component is also found in Alzheimer’s 
disease (AD). Several miRNAs previously linked to neurogenesis and neurodifferentiation 
were affected in a spatiotemporal manner in diseased patient brain samples and/or over 
different disease stages [39]. However, these changes were not reflected in cerebrospinal 
fluid (CSF) samples, but rather underexpression of miR-146b, a miRNA associated with 
inflammation, as well as miR-181a and miR-142, two miRNA previously associated with T 
cell activation and differentiation, was documented. The authors proposed that these changes 
were on account of upregulation of innate immune pathways in resident CSF lymphocytes as 
opposed to cellular infiltrate [39]. 
On account of reports of <70 nucleotide RNA in circulating blood, Mitchell et al. cloned and 
sequenced such molecules from the plasma of a healthy donor [40]. Amazingly, 93% of these 
clones corresponded to known  miRNA at concentrations of 0.9-1.3 e5 copies per ul of 
plasma, and were protected from RNase activity. Aiming to detect tumour-derived miRNA in 
plasma, a human prostate cancer cell line xenograft was implanted in immunocompromised 
mice. The process had no impact upon canonical plasma miRNA levels in the mouse, but two 
human-specific miRNA (miR-629* and miR-660) overexpressed in the xenograft were 
detected. By assaying for six biopsy-overexpressed miRNAs not present in healthy patient 
plasma the authors identified that miR-141 could distinguish diseased from healthy 
individuals with 60% sensitivity and 100% specificity. By re-examining previously published 
data on the miRnomes of various human cancers [41], retracing the evolutionary conservation 
of miR-141 back to zebrafish, and performing sequencing analyses of prostate stromal vs 
epithelial cell miRnomes, the authors demonstrated that this miRNA is representative of 
epithelial tissue [40]. Given that other epithelial cancers also overexpress miR-141 [41], it 
remains to be seen if plasma detection of miR-141 also is diagnostic of prostate cancer. 
At the same time, Chen et al. were employing NGS to investigate the broad utility of miRNA 
as serum biomarkers [42], documenting species- and sex-specific miRNA profiles in serum, 
and signatures of other cancers and diseases such as type II diabetes. Importantly, 4% of the 
detected miRNA were unique to blood cells whereas 6% were unique to serum, suggesting 
serum miRNAs are not cellular debris artefacts. In addition, 55 of the miRNA overexpressed 
in lung cancer patient sera were also detected in colorectal cancer patient sera. Unexpectedly, 
more than a third (38.5%) of the lung cancer-overexpressed miRNA were also detected in 
type II diabetes samples, probably a consequence of the common underlying inflammatory 
component, as alluded by the overexpression of inflammation-associated miRNA (e.g. miR-
146a) in both sample sets. Collectively, these data support the tenet that serum-based disease 
detection by means of miRNA profiling will require multiple as opposed to single or paired 
target expression assessment.  
Following these reports, serum or plasma miRNA detection has been proposed for ovarian 
cancer [43] and pregnancy [44].  However, circulating miRNA levels might also be highly 
sensitive to tissue damage. Following induction of hepatotoxicity in BALB/c mice through 
paracetamol overdose miRNA deregulation was observed in plasma as well as in the liver. 
Curiously, miR-122 was substantially downregulated in the liver but upregulated in plasma in 
a time- and dose-dependent fashion. This profile manifested in advance, and with higher 
sensitivity to plasma alanine aminotransferase (ALT) changes, a classical biomarker of liver 
damage [45]. Indeed, evidence from multiple angles now suggests that liver underexpression 
of miR-122 appears to be a hallmark of liver disease [46-49].  
 
Exosomal and mucosal miRNA 
What is the origin of these miRNAs in circulation? The relative stability of serum miRNAs 
[39, 41] has given rise to hypotheses of disease-communicating complexes [50]. Such 
functions are believed to be mediated by cell-derived microparticles such as exosomes. These 
are membranous vesicles of 40-100 nm diameter containing proteins, mRNA and miRNAs 
[51], believed to extensively mediate horizontal communication between numerous cell types 
both in vitro and in vivo, including stem cells, tumour cells, B cells, dendritic cells, mast 
cells, platelets, placental trophoblasts, glial cells and neurones [51-58]. In ovarian cancer the 
density of circulating exosomes has been reported to increase with disease state, whilst 
tumour-specific miRNA have been identified in these structures [54]. Similar data have been 
reported in lung adenocarcinoma, though in this case no correlation could be drawn against 
disease state [55]. Such exosome-associated miRNA signatures have been proposed as 
diagnostic biomarkers for both diseases [55, 59].  
Disease-associated signatures have also been recovered from mucosal biofluids, raising the 
tantalising prospect of non-invasive biomarker applications for miRNAs. Thus, miR-21 
expression analysis in non-small cell lung cancer (NSCLC) patient sputum could detect the 
disease with ~70% sensitivity and 100% specificity [60]. As in serum studies, sputum 
miRNAs were also resistant to RNase degradation. Similarly, miRNA-126 and miR-182 were 
found to be overexpressed in bladder cancer urine samples [61], with the miR-126:miR-152 
ratio being 72% sensitive and 82% specific to bladder cancer. Elsewhere, saliva samples were 
shown to be sources of relatively RNase-resistant miRNA, with levels of miR-125a and miR-
200a able to differentiate oral squamous cell carcinoma patients from healthy controls [62]. 
As with circulatory miRNA, early evidence suggest that the source of salivary miRNA may 
indeed be exosomes [63]. 
 
Conclusions  
Whilst commercialisation of miRNA-based assays for cancer has provided proof-of-concept 
for the utility of these biomolecules in diagnostics [22-25], the full potential behind this 
approach is only now beginning to emerge. The unexpected presence of miRNA in 
circulation [40, 42-45] and mucosal secretions [60-62] suggests that a wide variety of 
diseases might be possible to assay for using miRNAs. In addition, the kinetics of circulatory 
miR-122 levels in response to liver damage [45] indicate that miRNA might present novel, 
significantly improved, cross-species biomarker opportunities in toxicology and drug safety 
assessment. Human or in vivo data supportive of the utility of miRNA monitoring on drug 
efficacy might be presently lacking [15, 28, 36], however, the studies conducted so far have 
served to highlight a need for improved analytical procedures with regards to tissue sample 
collection. As a wide variety of diseases involve complex cellular environments, ‘whole 
biopsy’ analysis serves to identify composite signatures that may or may not reflect a range 
of diseases with commonly engaged processes, e.g. inflammation, complicating diagnosis. It 
is encouraging, however, that irrespective of these challenges, miRNA profiling might indeed 
be the road to end the quest for precise diagnostics for previously unaddressed diseases and 
personalised medicine.  
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Table 2: miRNA biomarker assays proposed for physiological condition   
Condition
Pancreatic ductal adenocarcinoma vs pancreatitis †
Squamous vs. non-squamous lung cancer †
Malignant pleural mesothelioma vs. pleural and lung cancers †
Identification of cancer of unknown primary origin †
Primary biliary cirrhosis
Renal allograft rejection











Non-small cell lung carcinoma
Bladder cancer
Oral squamous cell carcinoma 
†: Commericalised
‡: Mouse study on paracetamol toxicity
        n and disease diagnosis.
Tissue sampling Assay target(s) Sensitivity / Specificity (%) Reference
Pancreas biopsy miR-217, miR-196a 95 / 95 [22]
Lung biopsy miR-205, miR-21 91 / 97 [23]
Tumour biopsy miR-200c, miR-193a-3p, miR95 / 96 [24]
Tumour biopsy 48 miRNA panel, see referen90 / 99 [25]
Liver biopsy miR-122a, miR-26a, miR-99a    Not available [27]
Kidney biopsy miR-155, miR-142-5p 100 / 95 [29]
Synovial tissue miR-155, miR-146a Not available [33, 34]
PBMC's miR-16, miR-132, miR-146a, Not available [35]
Peripheral CD4+ T lymmiR-223 Not available [36]
CSF miR-146b, miR-181a, miR-14Not available [39]
Blood plasma miR-141 60 / 100 [40]
Blood serum miR-25, miR-223 Not available [42]
Blood serum miR-21, miR-29a, miR-92, m  Not available [43]
Blood plasma miR-526a, miR-527, miR-520Not available [44]
Blood plasma miR-122, miR-192 Not available [45]
Blood serum exosom miR-21, miR-141, miR-200a,      Not available [54]
Blood plasma exosommiR-17-3p, miR-21, miR-106          Not available [55]
Lung sputum miR-21 70 / 100 [60]
Urine miR-126:miR-152 ratio 72 / 82 [61]
Saliva miR-125a, miR-200a Not available [62]
